Canntab Therapeutics Limited (PILL.CN) Research

Canntab Therapeutics Limited, a phytopharmaceutical firm with its main office in Markham, Canada, is dedicated to the research and development of sophisticated, medical-grade cannabinoid compounds. The company's diverse portfolio within Canada includes various orally administered pharmaceutical cannabis products. These innovative dosage forms encompass extended-release cannabinoid pellets, rapid-onset cannabidiol options, multi-layered modified-release formulations, quickly dissolving flash-melt versions, and dual-layer cannabinoid tablets. Canntab's products are designed to address a wide spectrum of health concerns, such as sleep disturbances, post-traumatic stress disorder, social anxiety, different forms of addiction, arthritic conditions, general pain management, alleviating pain and stimulating appetite for cancer patients, and aiding in recovery from opioid and other painkiller dependencies.

Market snapshot

Symbol
PILL.CN
Price
$0.01
Day change
-50.00%
Market cap
$194.5K
P/E ratio
-0.05x
52-week range
0.0-0.125
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic

Peer companies

  • Avisa Diagnostics Inc. (AVBT.CN)
  • Gaia Grow Corp. (GAIA.CN)
  • Russell Investments Fallen Ange (HALO.NE)
  • Restart Life Sciences Corp. (HEAL.CN)
  • FSD Pharma Inc. (HUGE.CN)
  • Imagin Medical Inc. (IME.CN)
  • Kiaro Holdings Corp. (KO.V)
  • Lowell Farms Inc. (LOWL.CN)

Open Canntab Therapeutics Limited (PILL.CN) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.